This clinical trial is focused on studying the long-term safety and effectiveness of a treatment for a condition called systemic sclerosis associated interstitial lung disease (SSc-ILD). This condition is a type of lung disease that occurs in people with systemic sclerosis, a rare autoimmune disease that causes hardening and tightening of the skin and connective tissues. The treatment being studied is a medication called belimumab, which is given as an injection under the skin using a pre-filled pen.

The purpose of the study is to understand how safe and tolerable belimumab is for people with SSc-ILD over a long period. Participants in the study will receive belimumab injections and will be monitored regularly to check for any side effects and to see how their lung function changes over time. The study will continue for several years to gather comprehensive data on the treatment’s long-term effects.

Participants will be asked to visit the study site at specific intervals for assessments, which may include checking lung function and overall health. The study aims to provide valuable information on the use of belimumab for treating SSc-ILD, potentially offering a new option for managing this challenging condition.